Tag:
Afinitor
Latest Headlines
Latest Headlines
Another boost for Novartis' Afinitor in breast cancer
Novartis ( $NVS ) has delivered more promising data on Afinitor at the San Antonio Breast Cancer Symposium, spawning headlines all over. The drug, now approved for kidney and other cancers, extended
Roche, Novartis showcase game-changing breast cancer drug data
Roche and Novartis ( $NVS ) put out new data yesterday on two treatments that promise to fundamentally reshape the way the majority of breast cancer patients are treated. Roche clearly impressed
Afinitor data could be 'game-changer' in breast cancer
Novartis' ( $NVS ) hopes for Afinitor just got closer to reality. The drug more than doubled progression-free survival when added to standard hormonal therapy in post-menopausal women with
Roche, Novartis cancer meds win EMA nod
Roche and Novartis both got a boost from European authorities, who are recommending new uses for their targeted cancer drugs. Roche got the nod from European Medicines Agency to market Tarceva for
Another study-data boost for Novartis' Afinitor
More good news for Afinitor. The Novartis cancer drug shrank benign brain tumors in a new study, adding to its arsenal of data supporting new uses. The Phase III study of patients with subependymal
New breast-cancer data bolsters Novartis' Afinitor
Novartis halted a trial of Afinitor in advanced breast cancer patients because the drug had already met its goal of extending the time period before tumors began to grow again. Armed with this new
Novartis drug gets CHMP nod for new use
The Novartis drug everolimus looks to be racking up markets for its third brand name. Marketed as a treatment for kidney and pancreatic cancer under the name Afinitor and as an organ rejection drug
NICE issues final rebuff to Novartis' Afinitor
Novartis' battle to win over the UK's cost-effectiveness watchdog to its kidney cancer treatment Afinitor has hit a dead end, as the National Institute for Health and Clinical Excellence determined
Pfizer, Novartis drugs win advisory panel nod
FDA's expert advisors gave two thumbs up yesterday, one for Pfizer ( $PFE ) and one for Novartis ( $NVS ). The companies' cancer drugs Sutent and Afinitor won backing from the panel as treatments for a
Novartis, Pfizer see cancer data questioned
With cancer drugs, the first approval is only the beginning. An indication for one type of cancer can become two or three if drugmakers play their cards right--and if the treatments themselves prove
